« Back to Record
Citation APA

Bonnefoi, H., Piccart-Gebhart, M., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Blot, E., Zaman, K., Cufer, T., Lortholary, A., Lidbrink, E., André, S., Litière, S., Dal Lago, L., Becette, V., Cameron, D. A., Bergh, J., Iggo, R., & EORTC 10994/BIG 1-00 Study Investigators, (2011). TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet oncology, 12(6), 527-539. doi:10.1016/S1470-2045(11)70094-8


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/125377

Bonnefoi, H., Piccart-Gebhart, M., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Blot, E., Zaman, K., Cufer, T., Lortholary, A., Lidbrink, E., André, S., Litière, S., Dal Lago, L., Becette, V., Cameron, D. A., Bergh, J., Iggo, R., & EORTC 10994/BIG 1-00 Study Investigators, (2011). TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet oncology, 12(6), 527-539. doi:10.1016/S1470-2045(11)70094-8